EcoDrugPlus

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSLCAG00010024667
Gene Symbol: PARP3
1 Cross references
196 Possible Orthologues:

Polyunsaturated Fatty Acid Lipoxygenase Alox12-Like

Ensembl ID : ENSLCAG00010025249
Gene Symbol: LOC108879679
4 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSLCAG00010013453
Gene Symbol: PORCN
1 Cross references
193 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSLCAG00010007693
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSLCAG00010010371
Gene Symbol: KCNMA1
1 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSLCAG00010016713
Gene Symbol: KCNMA1
4 Cross references
239 Possible Orthologues:

Potassium Channel Subfamily K Member 2

Ensembl ID : ENSLCAG00010008840
Gene Symbol: LOC108895647
4 Cross references
213 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSLCAG00010019296
Gene Symbol: KCNK3A
1 Cross references
200 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSLCAG00010005137
Gene Symbol: LOC108900306
4 Cross references
218 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSLCAG00010018630
Gene Symbol: KCNJ11
1 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSLCAG00010026573
Gene Symbol: KCNJ2
4 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSLCAG00010025782
Gene Symbol: KCNJ2A
4 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).